vTv Therapeutics Email Format

Pharmaceutical ManufacturingNorth Carolina, United States51-200 Employees

vTv Therapeutics is a mid-sized biopharmaceutical company focused on developing oral, small molecule therapies for diabetes and other chronic diseases. Its lead program, cadisegliatin, is in Phase 3 and being studied as a potential first-in-class oral glucokinase activator for type 1 diabetes. The company is advancing multiple molecules across different chronic disease indications, often in collaboration with development partners. Cadisegliatin's safety and efficacy have not yet been established, and there is no guarantee of regulatory approval or commercial availability.

Based in High Point, North Carolina, vTv operates as a late-stage pharmaceutical company. In February 2026, vTv Therapeutics granted Newsoara Biopharma Co., Ltd., a China-based partner, an exclusive worldwide license to develop and commercialize its PDE4 inhibitor HPP737.

Get verified vTv Therapeutics emails free

Company overview Employee directory